BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25648635)

  • 21. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
    Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
    Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
    Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
    Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor.
    Park JY; Zheng W; Kim D; Cheng JQ; Kumar N; Ahmad N; Pow-Sang J
    Cancer Detect Prev; 2007; 31(5):359-65. PubMed ID: 18037591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of EphA5 by promoter methylation in human prostate cancer.
    Li S; Zhu Y; Ma C; Qiu Z; Zhang X; Kang Z; Wu Z; Wang H; Xu X; Zhang H; Ren G; Tang J; Li X; Guan M
    BMC Cancer; 2015 Jan; 15():18. PubMed ID: 25609195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancer.
    Wang Y; Ren F; Wang Y; Feng Y; Wang D; Jia B; Qiu Y; Wang S; Yu J; Sung JJ; Xu J; Zeps N; Chang Z
    Carcinogenesis; 2014 May; 35(5):983-91. PubMed ID: 24302614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
    Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
    Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
    Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer.
    Pastuszak-Lewandoska D; Kordiak J; Antczak A; Migdalska-Sęk M; Czarnecka KH; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska-Senderowska D; Brzeziańska-Lasota E
    Med Oncol; 2016 Jul; 33(7):75. PubMed ID: 27287342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells.
    Lee J; Han JH; Jang A; Kim JW; Hong SA; Myung SC
    PLoS One; 2016; 11(11):e0166664. PubMed ID: 27835705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of RASSF1 promoter methylation in prostate cancer.
    Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
    J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of DLEC1 promoter is a predictor for recurrence in Chinese patients with gastric cancer.
    Ye X; Feng G; Jiao N; Pu C; Zhao G; Sun G
    Dis Markers; 2014; 2014():804023. PubMed ID: 25574068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PLCD1 is a functional tumor suppressor inducing G(2)/M arrest and frequently methylated in breast cancer.
    Xiang T; Li L; Fan Y; Jiang Y; Ying Y; Putti TC; Tao Q; Ren G
    Cancer Biol Ther; 2010 Sep; 10(5):520-7. PubMed ID: 20657189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
    Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
    Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
    Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene promoter methylation in prostate tumor-associated stromal cells.
    Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
    J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High expression of DDX20 enhances the proliferation and metastatic potential of prostate cancer cells through the NF-κB pathway.
    Chen W; Zhou P; Li X
    Int J Mol Med; 2016 Jun; 37(6):1551-7. PubMed ID: 27121695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.